Cover Image
市場調查報告書

輻射中毒 (輻射病·急性輻射症候群) :開發中產品分析

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 229758
出版日期 內容資訊 英文 215 Pages
訂單完成後即時交付
價格
Back to Top
輻射中毒 (輻射病·急性輻射症候群) :開發中產品分析 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2017
出版日期: 2017年09月30日 內容資訊: 英文 215 Pages
簡介

輻射中毒(輻射病,急性游離輻射症候群)是在非常短的期間內(通常是僅數分鐘內)全身(或大範圍)穿過了高劑量的輻射線所引起的急性疾病。主要的原因是特別組織的未成熟實質性幹細胞的減少。常見的症狀有口鼻·牙齦的出血、血便、瘀傷、精神混亂、脫水、腹瀉、昏厥、疲勞等症狀。

本報告提供輻射中毒 (輻射病·急性輻射症候群) 的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

輻射中毒 (輻射病·急性輻射症候群)的概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

輻射中毒 (輻射病·急性輻射症候群) :企業開發中的治療藥

輻射中毒 (輻射病·急性輻射症候群) :大學/機關研究中的治療藥

輻射中毒 (輻射病·急性輻射症候群) :開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

輻射中毒 (輻射病·急性輻射症候群) :企業開發中的產品

輻射中毒 (輻射病·急性輻射症候群) :大學/機關研究中的產品

輻射中毒 (輻射病·急性輻射症候群)的治療藥的開發企業

  • Aeolus Pharmaceuticals, Inc.
  • Angion Biomedica Corp.
  • Atox Bio Inc.
  • Avaxia Biologics, Inc.
  • Bolder Biotechnology, Inc.
  • Caladrius Biosciences, Inc.
  • Cellerant Therapeutics, Inc.
  • Cellphire, Inc.
  • Chrysalis BioTherapeutics, Inc.
  • Cleveland BioLabs, Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Diffusion Pharmaceuticals Inc.
  • Eli Lilly and Company
  • GNI Group Ltd.
  • Humanetics Corporation
  • INSYS Therapeutics, Inc.
  • Meabco A/S
  • Neumedicines Inc.
  • Onconova Therapeutics, Inc.
  • PharmaIN Corporation
  • Pluristem Therapeutics Inc.
  • ProCertus BioPharm Inc.
  • RDD Pharma Ltd.
  • RedHill Biopharma Ltd.
  • RxBio, Inc.
  • Soligenix, Inc.
  • Stemedica Cell Technologies, Inc.
  • Terapio Corporation
  • Tonix Pharmaceuticals Holding Corp.

輻射中毒 (輻射病·急性輻射症候群) :治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

輻射中毒 (輻射病·急性輻射症候群) :最近的開發平台趨勢

輻射中毒 (輻射病·急性輻射症候群) :暫停中的計劃

輻射中毒 (輻射病·急性輻射症候群) :開發中止的產品

輻射中毒 (輻射病·急性輻射症候群) :產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9760IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2017, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline landscape.

Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 5, 8, 1, 44, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Development
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drug Profiles
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Ltd, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by AVM Biotechnology LLC, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by BCN Biosciences LLC, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellphire Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Chrysalis BioTherapeutics Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by FirstString Research Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Foresee Pharmaceuticals LLC, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Galera Therapeutics Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Genzyme Corp, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by GNI Group Ltd, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corp, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Insys Therapeutics Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Medesis Pharma SA, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Nohla Therapeutics Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Original BioMedicals Co Ltd, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by PharmaIN Corp, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RDD Pharma Ltd, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RedHill Biopharma Ltd, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Shuttle Pharmaceuticals LLC, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by SK Chemicals Co Ltd, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Synedgen Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by TSRL Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by viDA Therapeutics Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Windtree Therapeutics Inc, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top